This information is intended for US healthcare professionals.

Continue

Visit the patient site

FDA breakthrough therapy designation1

The HIV-1 capsid
The HIV-1 Capsid

FDA breakthrough therapy designation1

First-in-class, long-acting HIV-1 capsid inhibition with SUNLENCA®2,3

BREAKING
BARRIERS

in HIV treatment

Help heavily treatment-experienced (HTE) adults
break away from HIV-1 treatment failures by adding
SUNLENCA*, a novel HIV-1 capsid inhibitor2

SUNLENCA should always be taken with an optimized background regimen.

Discover how SUNLENCA works

For illustrative purposes only. Not actual patient.

For illustrative purposes only. Not actual patient.

Discover how SUNLENCA works

Help heavily treatment-experienced (HTE)
adults break away from HIV-1 treatment
failures by adding SUNLENCA*, a novel
HIV-1 capsid inhibitor2

SUNLENCA should always be taken with an optimized background regimen.

Important Safety Information

Contraindications

  • Coadministration: Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers.

A novel, first-in-class
capsid inhibitor1-3

SUNLENCA received FDA breakthrough therapy designation and has a novel MOA that inhibits capsid function at multiple stages of the HIV-1 lifecycle.

Watch a video to see the role the capsid protein plays in HIV-1 replication and how SUNLENCA targets these essential functions.

View MOA video

Click for Important Safety Information for SUNLENCA.

Demonstrated potent antiviral activity2,5

See the data from CAPELLA, a 52-week, partially randomized, placebo-controlled, double-blind, multicenter trial studying the efficacy and safety of SUNLENCA in HTE HIV-1 patients with multidrug resistance (N=72).

88% of patients taking SUNLENCA (n=24) achieved the primary endpoint, the proportion of patients in the randomized cohort achieving ≥0.5 log10 copies/mL reduction from baseline in HIV-1 RNA at Day 15, vs 17% of patients taking placebo (n=12).

Adverse reactions

  • Most common adverse reactions (incidence ≥3%, all grades) through Week 52 were injection site reactions (65%) and nausea (4%).
Explore the efficacy

For illustrative purposes only. Not actual patient.

Administered only twice a year In Addition to an OBR2,*

SUNLENCA, when combined with an optimized background regimen (OBR), offers HTE adults a long-acting treatment option.

Prior to starting every-6-month subcutaneous injections, patients should complete an initiation regimen listed in the dosing section.

Missed Dose: During the maintenance period, if more than 28 weeks have elapsed since the last injection and if clinically appropriate to continue SUNLENCA treatment, restart the initiation dosage regimen from Day 1, Option 1 or Option 2.

Learn about dosing

INDICATION

SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Important Safety Information

Contraindications

  • Coadministration: Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers.

Warnings and precautions

  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported in patients treated with combination antiretroviral (ARV) therapy.

INDICATION

SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Tap for Important Safety Information

Important Safety Information

Contraindications

  • Coadministration: Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers.

Warnings and precautions

  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported in patients treated with combination antiretroviral (ARV) therapy.

INDICATION

SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

  • Long-acting properties and potential associated risks with SUNLENCA: Residual concentrations of SUNLENCA may remain in the systemic circulation of patients for up to 12 months or longer. SUNLENCA may increase exposure, and potential risk of adverse reactions, to drugs primarily metabolized by CYP3A initiated within 9 months after last injection. Counsel patients regarding the dosing schedule because nonadherence could lead to loss of virologic response and development of resistance. If virologic failure occurs, switch to an alternative regimen if possible. If discontinuing SUNLENCA, begin alternate suppressive ARV regimen within 28 weeks from last injection.
  • Injection site reactions may occur, and nodules and indurations may be persistent.

Adverse reactions

  • Most common adverse reactions (incidence ≥3%, all grades) are injection site reactions (65%) and nausea (4%).

Drug interactions

  • Prescribing information: Consult the full prescribing information for SUNLENCA for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.
  • Enzymes/transporters: Drugs that are strong or moderate inducers of CYP3A may significantly decrease the concentration of SUNLENCA. Drugs that strongly inhibit CYP3A, P-gp, and UGT1A1 together may significantly increase the concentration of SUNLENCA. SUNLENCA may increase the exposure of drugs primarily metabolized by CYP3A, when initiated within 9 months after the last injection of SUNLENCA, which may increase the potential risk of adverse reactions.

Dosage and administration

  • Dosage: Initiation with 1 of 2 options, followed by maintenance dosing once every 6 months. Tablets may be taken with or without food.
    • Initiation Option 1: Day 1: 927 mg by subcutaneous injection and 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally (2 x 300-mg tablets).
    • Initiation Option 2: Day 1: 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally (2 x 300-mg tablets). Day 8: 300 mg orally (1 x 300-mg tablet). Day 15: 927 mg by subcutaneous injection.
    • Maintenance: 927 mg by subcutaneous injection every 26 weeks +/- 2 weeks from date of last injection.
  • Missed Dose: During the maintenance period, if more than 28 weeks have elapsed since the last injection and if clinically appropriate to continue SUNLENCA treatment, restart the initiation dosage regimen from Day 1, Option 1 or Option 2.

Pregnancy and lactation

  • Pregnancy: There is insufficient human data on the use of SUNLENCA during pregnancy. An Antiretroviral Pregnancy Registry (APR) has been established.
  • Lactation: Individuals infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.

Please see full Prescribing Information for SUNLENCA.